ethyl 2-(2-(3,5-dichloro-4-hydroxybenzoyl)hydrazinyl)-2-oxoacetate | 1251921-56-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl 2-(2-(3,5-dichloro-4-hydroxybenzoyl)hydrazinyl)-2-oxoacetate
• 英文别名: ethyl 2-[2-(3,5-dichloro-4-hydroxybenzoyl)hydrazinyl]-2-oxoacetate
• CAS: 1251921-56-8
• 化学式: C₁₁H₁₀Cl₂N₂O₅
• 分子量: 321.117
• InChiKey: VCSSIFIVROPEGO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  105
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 2-(2-(3,5-dichloro-4-hydroxybenzoyl)hydrazinyl)-2-oxoacetate 在 三氯氧磷 、 水 、 二氯甲烷 、 Brine 、 magnesium sulfate 、 silica gel 、 methanol-dichloromethane 作用下， 以 三氯氧磷 为溶剂， 反应 23.0h， 以to give 0.6649 g (34%) of the title compound as a white solid的产率得到ethyl 5-(3,5-dichloro-4-hydroxyphenyl)-1,3,4-oxadiazole-2-carboxylate
  参考文献：
  名称：

  COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES

  摘要：

  本发明涉及用于治疗动物疾病的组合物和方法，该疾病对抑制功能性囊性纤维化跨膜传导调节因子（CFTR）多肽敏感，通过向需要的哺乳动物投予本文所定义的化合物的有效量（包括在表1-2中列出的那些化合物或由公式I-IV包围的化合物）或包含这些化合物的组合物，从而治疗该疾病。本发明特别涉及一种治疗腹泻和多囊肾病的方法。

  公开号：

  US20120136003A1
• 作为产物：
  描述：

  3,5-二氯-4-羟基苯肼 、 草酰氯单乙酯 在 氮气 、 ice water 、 二氯甲烷 作用下， 以 二氯甲烷 为溶剂， 反应 72.33h， 以to give 2.046 g (70%) of the title compound as a white solid的产率得到ethyl 2-(2-(3,5-dichloro-4-hydroxybenzoyl)hydrazinyl)-2-oxoacetate
  参考文献：
  名称：

  COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES

  摘要：

  本发明涉及用于治疗动物疾病的组合物和方法，该疾病对抑制功能性囊性纤维化跨膜传导调节因子（CFTR）多肽敏感，通过向需要的哺乳动物投予本文所定义的化合物的有效量（包括在表1-2中列出的那些化合物或由公式I-IV包围的化合物）或包含这些化合物的组合物，从而治疗该疾病。本发明特别涉及一种治疗腹泻和多囊肾病的方法。

  公开号：

  US20120136003A1

文献信息

• Compounds, Compositions and Methods Comprising 4N-Substituted Triazole Derivatives
  申请人：Russell Michael Geoffrey Neil

  公开号：US20100267725A1

  公开（公告）日：2010-10-21

  The present invention relates to compounds, compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Table 1 or 2 or encompassed by formula I) or compositions comprising these compounds, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease.

  本发明涉及化合物、组合物和治疗动物疾病的方法，该疾病对通过给予需要的哺乳动物有效量的本文中定义的化合物（包括表1或2中列出的那些化合物或公式I所包含的化合物）或包含这些化合物的组合物来抑制功能性囊性纤维化跨膜传导调节蛋白（CFTR）多肽敏感，从而治疗该疾病。本发明特别涉及一种治疗腹泻和多囊性肾病的方法。
• COMPOUNDS, COMPOSITIONS, AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES
  申请人：de Hostos Eugenio L.

  公开号：US20110288103A1

  公开（公告）日：2011-11-24

  The present invention relates to methods for treating a disease in an animal, which disease is responsive to blocking of calcium activated chloride echannel (CaCC) by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-2 or encompassed by formulas I-IV) or compositions thereof, thereby treating the disease.

  本发明涉及一种治疗动物疾病的方法，该疾病对钙激活氯离子通道（CaCC）的阻断有反应，通过向需要的哺乳动物施用本文所定义的化合物（包括表1-2中列出的化合物或公式I-IV所包含的化合物）或其组合物的有效量，从而治疗该疾病。
• [EN] COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES<br/>[FR] COMPOSÉS, COMPOSITIONS ET MÉTHODES COMPRENANT DES DÉRIVÉS DU 1,3,4-OXADIAZOLE
  申请人：INST ONEWORLD HEALTH

  公开号：WO2010123933A1

  公开（公告）日：2010-10-28

  The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-2 or encompassed by formulas I-IV) or compositions comprising these compounds, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease.
• [EN] COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES<br/>[FR] COMPOSÉS, COMPOSITIONS ET MÉTHODES IMPLIQUANT DES DÉRIVÉS DE 1,3,4-OXADIAZOLE
  申请人：INST ONEWORLD HEALTH

  公开号：WO2011133596A1

  公开（公告）日：2011-10-27

  The present invention relates to methods for treating a disease in an animal, which disease is responsive to blocking of calcium activated chloride echannel (CaCC) by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-2 or encompassed by formulas I-IV) or compositions thereof, thereby treating the disease.
• COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES
  申请人：Russell Michael Geoffrey Neil

  公开号：US20120136003A1

  公开（公告）日：2012-05-31

  The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-2 or encompassed by formulas I-IV) or compositions comprising these compounds, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease.

  本发明涉及用于治疗动物疾病的组合物和方法，该疾病对抑制功能性囊性纤维化跨膜传导调节因子（CFTR）多肽敏感，通过向需要的哺乳动物投予本文所定义的化合物的有效量（包括在表1-2中列出的那些化合物或由公式I-IV包围的化合物）或包含这些化合物的组合物，从而治疗该疾病。本发明特别涉及一种治疗腹泻和多囊肾病的方法。